驱动基因阳性晚期非小细胞肺癌靶向治疗

Targeted therapy for advanced non-small cell lung cancer with driver gene-positive

近年来,分子靶向治疗有效改善了驱动基因阳性晚期非小细胞肺癌(NSCLC)患者的预后,其中,针对存在人体表皮生长因子受体基因突变、棘皮动物微管相关样蛋白4-间变性淋巴瘤激酶融合基因、ROS1基因重排等的NSCLC患者,疗效尤为显著。对于驱动基因阳性晚期NSCLC患者,靶向治疗药物的选择尤为重要。

In recent years,molecular targeted therapy has effectively improved the prognosis of advanced non-small cell lung cancer(NSCLC)patients with driver gene-positive,of which the efficacy is particularly significant for NSCLC patients with human epidermal growth factor receptor gene mutation,echinoderm microtubule-associated protein-4-anaplastic lymphoma kinase fusion gene,ROS1 gene rearrangement,etc.The selection of targeted therapy drugs is particularly important for advanced NSCLC patients with positive driver genes.